INMED PHARMACEUTICALS INC. Revenue from Contract with Customer, Excluding Assessed Tax
INMED PHARMACEUTICALS INC. (INM) reported Revenue from Contract with Customer, Excluding Assessed Tax of $1.37 million for the 12-month period ending 2022-06-30, per its 10-K filed 2022-09-23.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2022-09-23
- INMED PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $791.08K, a 10.17% decline year-over-year.
- INMED PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-03-31 was $309.58K, a 29.21% decline year-over-year.
- INMED PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-12-31 was $265.09K, a 4.23% decline year-over-year.
- INMED PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-09-30 was $0.00.
- INMED PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.37M, a 28.27% decline from fiscal 2021.
- INMED PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $1.90M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-06-30 | $791.08K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $1.10M derived: sum of 2 quarters · filed 2022-09-23 | $1.37M derived: sum of 3 quarters · filed 2022-09-23 | $1.37M 10-K · filed 2022-09-23 |
| 2022-03-31 | $309.58K 10-Q · filed 2022-05-13 | $574.68K derived: sum of 2 quarters · filed 2022-05-13 | $574.68K 10-Q · filed 2022-05-13 | $1.46M derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-12-31 | $265.09K 10-Q · filed 2022-02-14 | $265.09K 10-Q · filed 2022-02-14 | $1.15M derived: sum of 3 quarters · filed 2022-09-23 | $1.58M derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-09-30 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2022-09-23 | $880.63K derived: sum of 2 quarters · filed 2022-09-23 | $1.32M derived: sum of 3 quarters · filed 2022-09-23 | $1.59M derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-06-30 | $880.63K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $1.32M derived: sum of 2 quarters · filed 2022-09-23 | $1.59M derived: sum of 3 quarters · filed 2022-09-23 | $1.90M 10-K · filed 2022-09-23 |
| 2021-03-31 | $437.31K 10-Q · filed 2022-05-13 | $714.10K derived: sum of 2 quarters · filed 2022-05-13 | $1.02M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $276.79K 10-Q · filed 2022-02-14 | $586.07K 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |